Third Rock and Arie Bellde­grun’s firm come to­geth­er for CD20/CD3 bis­pe­cif­ic out of Chi­na

An­oth­er CD20/CD3 bis­pe­cif­ic is en­ter­ing the fold, ex­cept this time for au­toim­mune dis­eases.

Pro­lif­ic biotech cre­ator Third Rock Ven­tures and Arie Bellde­grun’s Two Riv­er have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER